You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,106,021


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,106,021
Title:Benzylbenzene derivatives and methods of use
Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
Inventor(s): Chen; Yuanwei (North Haven, CT), Cheng; Huawei (Shanghai, CN), Li; Shengbin (Shanghai, CN), Wu; Yuelin (Shanghai, CN), Feng; Yan (Shanghai, CN), Lv; Binhua (Shanghai, CN), Xu; Baihua (Shanghai, CN), Seed; Brian (Boston, MA), Hadd; Michael J. (San Diego, CA), Song; Yanli (Shanghai, CN), Du; Jiyan (Shanghai, CN), Wang; Congna (Shanghai, CN), Roberge; Jacques Y. (Shanghai, CN)
Assignee: Theracos, Inc. (Sunnyvale, CA)
Application Number:12/917,367
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,106,021
Patent Claims:1. A method of treating a disease or condition selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus and obesity, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: ##STR00115## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein said disease or condition is type 1 diabetes mellitus.

3. The method of claim 1, wherein said disease or condition is type 2 diabetes mellitus.

4. The method of claim 1, wherein said disease or condition is obesity.

5. The method of claim 1, wherein said compound is administered in combination with a second therapeutic agent.

6. The method of claim 5, wherein said second therapeutic agent is selected from the group consisting of antidiabetic agents, lipid-lowering/lipid-modulating agents, agents for treating diabetic complications, anti-obesity agents, antihypertensive agents, antihyperuricemic agents, and agents for treating chronic heart failure or atherosclerosis.

7. The method of claim 6, wherein said antidiabetic agent is selected from the group consisting of insulin and insulin mimetics, sulfonylureas, insulin secretion enhancers, biguanides, sulfonylurea/ biguanide combinations, meglitinides, thiazolidinediones, thiazolidinedione/ biguanide combinations, oxadiazolidinediones, PPAR-gamma agonists, PPAR-alpha/gamma dual agonists, PPAR-alpha/gamma/delta pan agonists, retinoid X receptor agonists, alpha-glucosidase inhibitors, stimulants of insulin receptor tyrosine kinase, tripeptidyl peptidase II inhibitors, dipeptidyl peptidase IV inhibitors, protein tyrosine phosphatase-1B inhibitors, glycogen phosphorylase inhibitors, glucose-6-phosphatase inhibitors, fructose 1,6-bisphosphatase inhibitors, pyruvate dehydrogenase inhibitors, imidazoline derivatives, hepatic gluconeogenesis inhibitors, D-chiroinositol, glycogen synthase kinase-3 inhibitors, incretin mimetics, GLP-1, GLP-1 analogs, GLP-1 receptor agonists, amylin, amylin analogs and agonists, aP2 inhibitors, beta-3 adrenergic receptor agonists, and other insulin sensitivity enhancers.

8. The method of claim 7, wherein said sulfonylurea is selected from the group consisting of glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glisoxepide, glyburide, and glyclopyramide.

9. The method of claim 7, wherein said biguanide is metformin.

10. The method of claim 7, wherein said meglitinide is selected from the group consisting of repaglinide, nateglinide, and mitiglinide.

11. The method of claim 7, wherein said thiazolidinedione is selected from the group consisting of rosiglitazone, pioglitazone, and CLX-0921.

12. The method of claim 7, wherein said alpha-glucosidase inhibitor is selected from the group consisting of acarbose and miglitol.

13. The method of claim 7, wherein said dipeptidyl peptidase IV inhibitor is selected from the group consisting of sitagliptin, saxagliptin and vildagliptin.

14. The method of claim 7, wherein said incretin mimetic is exenatide.

15. The method of claim 7, wherein said GLP-1 analog is liraglutide.

16. The method of claim 7, wherein said amylin analog is pramlintide.

17. The method of claim 6, wherein said anti-obesity agent is selected from the group consisting of serotonin-norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, norepinephrine releasing stimulants, anorexiants, dopamine agonists, H.sub.3-histamine antagonists, 5-HT2c receptor agonists, beta-3 adrenergic receptor agonists, cholecystokinin agonists, antidepressant/acetylcholinesterase inhibitor combinations, lipase inhibitors, anti-epileptic agents, leptin, leptin analogs and leptin receptor agonists, NPY receptor antagonists and modulators, ciliary neurotrophic factor, thyroid hormone receptor-beta agonists, cannabinoid CB1 receptor antagonists, melanin-concentrating hormone receptor antagonists, melanocortin-4 receptor agonists, selective muscarinic receptor M.sub.1 antagonists, opioid receptor antagonists, and combinations thereof.

18. The method of claim 17, wherein said norepinephrine-dopamine reuptake inhibitor is bupropion.

19. The method of claim 17, wherein said selective serotonin reuptake inhibitor is selected from the group consisting of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.

20. The method of claim 17, wherein said anorexiant is phentermine.

21. The method of claim 17, wherein said anti-epileptic agent is topiramate.

22. The method of claim 17, wherein said selective muscarinic receptor M.sub.1 antagonist is telenzepine.

23. The method of claim 17, wherein said opioid receptor antagonist is naltrexone.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.